The pharmaceutical landscape witnessing a revolution with the emergence of novel glucagon-like peptide-1 (GLP-1) receptor agonists. These innovative drugs demonstrate immense potential in managing type 2 diabetes and, https://luluguqu997098.dsiblogger.com/68926756/novel-glp-1-receptor-agonists-retatrutide-cagrillintide-tirzepatide-and-semaglutide